80 related articles for article (PubMed ID: 9685058)
21. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of cremophor EL with bolus doxorubicin.
Millward MJ; Webster LK; Rischin D; Stokes KH; Toner GC; Bishop JF; Olver IN; Linahan BM; Linsenmeyer ME; Woodcock DM
Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
[TBL] [Abstract][Full Text] [Related]
23. Indocyanine green plasma clearance in normal human males and females.
Mikulecký M
Acta Med Acad Sci Hung; 1976; 33(2):133-41. PubMed ID: 1030567
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
25. The liver profile in patients with hepatitis C virus and/or fascioliasis.
Wahib AA; el-Nasr MS; Mangoud AM; el-Shazly AM; Morsy AT
J Egypt Soc Parasitol; 2006 Aug; 36(2):405-40. PubMed ID: 16927859
[TBL] [Abstract][Full Text] [Related]
26. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion.
Iwasaki T; Ku Y; Kusunoki N; Tominaga M; Fukumoto T; Muramatsu S; Kuroda Y
Cancer Res; 1998 Aug; 58(15):3339-43. PubMed ID: 9699664
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
Kobayashi S; Wada H; Hama N; Akita H; Kawamoto K; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1325-33. PubMed ID: 24121480
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
29. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis.
Ott P; Keiding S; Bass L
Hepatology; 1993 Dec; 18(6):1504-15. PubMed ID: 8244277
[TBL] [Abstract][Full Text] [Related]
30. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
[No Abstract] [Full Text] [Related]
31. Dye clearance studies in Rotor's syndrome.
Kawasaki H; Kimura N; Irisa T; Hirayama C
Am J Gastroenterol; 1979 Apr; 71(4):380-8. PubMed ID: 453129
[TBL] [Abstract][Full Text] [Related]
32. The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.
Müller HJ; Port RE; Grubert M; Hilger RA; Scheulen M; Mross K;
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):598-9. PubMed ID: 14692710
[No Abstract] [Full Text] [Related]
33. Nine cases with marked retention of indocyanine green test and normal sulfobromophthalein test without abnormal liver histology: constitutional indocyanine green excretory defect.
Namihisa T; Nambu M; Kobayashi N; Kuroda H
Hepatogastroenterology; 1981 Feb; 28(1):6-12. PubMed ID: 7216141
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis.
Di Stefano G; Fiume L; Domenicali M; Busi C; Chieco P; Kratz F; Lanza M; Mattioli A; Pariali M; Bernardi M
Dig Liver Dis; 2006 Jun; 38(6):404-8. PubMed ID: 16595196
[TBL] [Abstract][Full Text] [Related]
35. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
36. Preliminary study of indocyanine green clearance in primary biliary cirrhosis.
Clements D; Elias E; McMaster P
Scand J Gastroenterol; 1991 Jan; 26(1):119-23. PubMed ID: 2006392
[TBL] [Abstract][Full Text] [Related]
37. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
38. [The pharmacokinetics of doxorubicin].
Erttmann R; Grandt M; Erb N; Garbrecht M; Landbeck G
Klin Padiatr; 1986; 198(3):271-6. PubMed ID: 3723990
[TBL] [Abstract][Full Text] [Related]
39. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
40. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
